ABIVAX Stock: +4.2% at Close, Despite a Weekly Decline of -4.23%
Abivax shares closed higher on Thursday, October 23, gaining 4.2% to 79.30 euros. This rebound follows a week of decline, where the stock fell by 4.23% over the last seven days. Despite this short-term volatility, the biotech value has recorded exceptional performances over longer horizons, with a gain of 791% over three months and 719.2% over twelve months.
Daily Trading Dynamics
The stock started the day around 76.10 euros and progressed steadily throughout the session, closing at 79.30 euros. This 4.2% increase occurred in a context where the CAC 40 also moderately increased by 0.23%, suggesting a slight positive momentum in the French market. However, trading volume remains limited, with only 0.08% of the capital traded, reflecting contained liquidity despite significant activity characterizing the stock in recent weeks. Technically, the stock is now significantly above its main moving averages. The 50-day moving average is at 71.44 euros, while the 200-day moving average remains at 26.81 euros.
This configuration suggests a bullish trend structure over intermediate and long terms, with the price operating well above these reference thresholds. The stock is within the Bollinger Bands, between 67.22 euros (lower limit) and 85.14 euros (upper limit), offering potential up to the resistance identified at 83.60 euros. The support threshold is at 68.60 euros, approximately 13.4% below current levels. This performance contrasts strongly with the gains made over longer periods. Over three months, the stock has advanced by 791%, while the annual gain reaches 719.2%, reflecting a dynamic value recovery initially depressed. These figures illustrate the volatile nature of biotechnological stocks, subject to significant amplifications when positive catalysts or turnaround anticipations emerge.
Technical Indicators Review
From a technical perspective, several signals show underlying tensions. The Relative Strength Index (RSI) is at 61, in a neutral zone slightly leaning towards buying, while the stochastic displays a sell signal. The MACD line is at 1.90 against a signal line at 1.94, generating a negative histogram of -0.04, revealing an emerging divergence. The On-Balance Volume (OBV) index shows a negative value of -227,901, while the Cumulative Money Flow (CMF) is at -0.23, suggesting a moderate accumulation of selling pressure. Volatility remains high, with a monthly ATR of 1.99 and a one-month volatility of 11.82%, typical of biotech growth stocks. The beta of -0.24 indicates a low correlation with the overall market, accentuating the idiosyncratic nature of the stock.
